Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasms 2Plasmacytoma 1Pathologic Complete Response 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Hepatic Insufficiency 1Hematologic Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pirtobrutinib 6Cyclophosphamide 6Mycophenolic Acid 5fludarabine phosphate 4fludarabine 4Rituximab 4Melphalan 4Azacitidine 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mesna 3Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Lenalidomide 2Cyclosporine 2Busulfan 2Brentuximab Vedotin 2Bone Marrow Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2zanubrutinib 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1idelalisib 1idecabtagene vicleucel 1cedazuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cc-486 × 1 year × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡